Olympus America

Press Center

Olympus Previews TANGO™ Benchtop Blood Bank Analyzer -- Automation For ABO/Rh Testing and Antibody Screening


Los Angeles, July 27, 2004 - Olympus is previewing the next addition to its line of blood bank systems, the new TANGO™ benchtop analyzer, at the American Association for Clinical Chemistry national meeting and Clinical Lab Exposition in Los Angeles this week.

TANGO is designed for transfusion services, donor centers and reference laboratories performing ABO/Rh testing and antibody screening. It is capable of performing a host of functions including blood group determination; antibody screening and identification; phenotyping; and compatibility testing.

With a throughput of 200 wells per hour, TANGO will provide laboratorians a more efficient tool in areas where real estate is tight and functionality is key. The benchtop analyzer measures just 4.2 (L) x 2.2 (W) x 2.4 (H) feet and weighs 286 lbs. It will perform pipetting sequences of liquids and subsequent analysis of agglutination reactions. The fully automated process will include positive sample identification; process control through automated recording of reagents (lot numbers, expiration dates); sample dilutions; reagent addition and mixing; incubation; washing; centrifugation and image analysis.

For greater flexibility, TANGO systems will also feature batch and random access operating modes and STAT sample interrupt. For easy use and maximum efficiency, TANGO will use a Windows® NT operating system, Pentium® processor, touch screen interface and image analysis software.

The TANGO system is available in Europe. Phase I U.S. field trials for ABO/Rh, antibody screening and donor confirmation testing have been completed, with U.S. market release anticipated in late 2004. Phase II field trials will begin in the fall of 2004 for additional applications including phenotyping, antibody identification and compatibility testing on the TANGO instrument. Olympus will offer a variety of acquisition options including leases, cost per test programs and outright instrument purchase.

For additional information, please contact Marie Foyt, Product Manager, Olympus Diagnostic Systems Group, at (800) 628-7152, ext. 2623. Fax: (972) 432-9532. Email: Marie.Foyt@olympus.com

About Olympus Diagnostic Systems Group
Olympus Diagnostic Systems Group provides innovative solutions that meet the high productivity demands of hospitals, integrated healthcare delivery networks, reference labs, blood banks and pharmaceutical labs. Olympus offers the broadest standardized line of random access chemistry-immuno analyzers, along with lab automation systems, comprehensive patient safety systems, blood bank analyzers and reagents. Olympus solutions save laboratories time, enhance patient safety, maximize productivity, and deliver fast, reliable results.

About Olympus
Olympus is a precision technology leader, designing and delivering innovative solutions in healthcare and consumer electronics worldwide.

Olympus works collaboratively with its customers and its parent company, Tokyo-based Olympus Corporation, to leverage R&D investment in precision technology and manufacturing processes across diverse business lines. These include:

  • Gastrointestinal endoscopes, accessories, and minimally invasive surgical products;
  • Advanced clinical and research microscopes;
  • Lab automation systems, chemistry-immuno and blood bank analyzers and reagents; and
  • Digital and film cameras, and digital voice recorders.
  • In the U. S. and Canada, Olympus serves healthcare, scientific and commercial laboratory markets with integrated product solutions and financial, educational and consulting services that help customers efficiently, reliably, safely, and easily achieve superior results. Olympus is the leader in gastrointestinal endoscopy and clinical and educational microscopes. The company's market-leading consumer electronics business spans North and South America. For more information, visit www.olympusamerica.com.